| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------------------|-------|------------------------------------|---------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | A WORLD WITHOUT INFECTIOUS DISEASE | | | | | | | | | | Vir August 2020 | | | Biotechnology, Inc. | | | | | | | Legal disclaimers Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir Biotechnology, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 81-2730369 (State or other jurisdict ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir Biotechnology, Inc. Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sec ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 1-39083 Vir Biotechnology, Inc. (Exact name of Registrant as specified in its Charter) | Delaware | 81-2730369 | | --- | --- | | (State o ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------------------------|-------|------------------------------------------|---------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | A WORLD WITHOUT INFECTIOUS DISEASE | | | | | | | | | | Vir | | | Biotechnology, Inc. | | | | | | | | | 38th January 14, 2020 | | Annual J.P. Morgan Healthcare Conference | | | | | | | | Legal disclaimers Forward-Looking Statements ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir Biotechnology, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 81-2730369 (State or other juri ...